NCT04754555

Brief Summary

Upper limb impairment occurs in approximately 70 to 80 per cent of adults post stroke. These impairments will have consequences on functional performance in activities of daily living and hence quality of life. Assessment of upper limb function is a component of rehabilitation that contributes to the selection of optimal interventions according to patient individualized needs. The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance that is only available in it's English version. The aim of this study is to translate and conduct a cross-cultural adaptation of the ArmA is order to investigate its psychometric properties through a validation study among stroke patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 9, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 9, 2021

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

February 10, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 15, 2021

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 9, 2023

Completed
Last Updated

February 15, 2021

Status Verified

February 1, 2021

Enrollment Period

Same day

First QC Date

February 10, 2021

Last Update Submit

February 10, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Measure OF ArmA inter-rater (test-retest) reproducibility values as measured by intra class coefficients ICC2

    The primary outcome measure will be ArmA inter-rater (test-retest) reproducibility values as measured by intra class coefficients ICC2,1. Data collection on perceived upper limb performance with the two-step F-ArmA measurement (T0 and T1) will allow the primary outcome (ICC2,1) to be calculated to establish inter-rater reproducibility. ArmA and MAL will be administered on 3 separate occasions by 2 separate assessors.

    first day of hospitalisation

  • Measure OF ArmA inter-rater (test-retest) reproducibility values as measured by intra class coefficients ICC2

    A secondary independent assessor (E2) will assess ArmA and MAL

    2 to 7 days of first assessment (T0)

Study Arms (2)

subacute phase

between 7 days and 6 months post-stroke;

Other: Arm Activity Measure (ArmA) in french

chronic phase

minimum 6 months post-stroke

Other: Arm Activity Measure (ArmA) in french

Interventions

The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance

chronic phasesubacute phase

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

adults with subacute and chronic stroke

You may qualify if:

  • age \> 18 with principle diagnosis of first-time ischemic or hemorrhagic stroke at least 7 days since onset and confirmed by MRI or CT;
  • participant having returned home from hospitalization at least one night if stroke time since onset is \<6 months or resides at home if \>6 months since stroke onset;
  • participant can maintain attention for questions for at least 30 minutes;
  • motivation to participate and having given informed written consent.

You may not qualify if:

  • subscale of aphasia severity from the Boston Diagnostic Aphasia Examination ≤3 indicating insufficient comprehension and expression for testing;
  • subscale score of ≥2 on the agnosia Unilateral Negligence Assessment Battery (BEN) indicating unilateral neglect.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UHToulouse

Toulouse, 31000, France

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Claire VILLEPINTE

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 10, 2021

First Posted

February 15, 2021

Study Start

February 9, 2021

Primary Completion

February 9, 2021

Study Completion

February 9, 2023

Last Updated

February 15, 2021

Record last verified: 2021-02

Locations